Table 4.
Clinical trials on phosphatidylinositol 3 kinase/Akt inhibitors in combination with DNA-targeted agents
| PI3K/Akt inhibitor | Target(s) | Combination arm(s) | Condition | Trial phase/status | Trial/registration |
| MK-2206 | Akt | Carboplatin + paclitaxel, docetaxel, erlotinib | Locally advanced, metastatic solid tumors | I/completed (published) | NCT00848718/February 2009[170] |
| Paclitaxel, trastuzumab | HER2-overexpressing advanced solid tumors | I/completed (abstract is published) | NCT01235897/November 2010[171] | ||
| Paclitaxel | Adult solid neoplasm, | I/ongoing (unpublished) | NCT01263145/December 2010 | ||
| recurrent or metastatic breast cancer | |||||
| Perifosine | PI3K/Akt | Docetaxel, prednisone | Neoplasms | I/completed (abstract is published) | NCT00399087/November 2006[172] |
| Docetaxel | Recurrent ovarian cancer | I/completed (abstract is published) | NCT00431054/February 2007[173] | ||
| Paclitaxel | Neoplasms | I/completed (abstract is published) | NCT00399126/November 2006[174] | ||
| Gemcitabine | Neoplasms | I/completed (abstract is published) | NCT00398697/November 2006[175] | ||
| Radiation | Solid tumors | I/published | Vink et al[176] | ||
| Radiation | Biochemically recurrent, hormone-sensitive prostate cancer with previous prostatectomy and/or radiation therapy | II/published | Chee et al[177] | ||
| BEZ235 | PI3K/mTOR | BEZ235 + paclitaxel, BKM120 + paclitaxel, BEZ235 + paclitaxel + trastuzumab, BKM120 + paclitaxel + trastuzumab | Metastatic or locally advanced solid tumors | I/completed (abstract is published) | NCT01285466/January 2011[178] |
| Paclitaxel | Inoperable locally advanced breast cancer, metastatic breast cancer | I and II/completed (abstract is published) | NCT01495247/September 2011[179] |
HER2: Human epidermal growth factor receptor 2; PI3K: Phosphatidylinositol 3 kinase; mTOR: Mammalian target of rapamycin.